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Abstract
OBJECTIVE: To evaluate the efficacy of integrated
Traditional Chinese Medicine-Western Medicine
(TCM-WM) in the treatment of acute onset pulmo-
nary heart disease (PHD).
METHODS: A total of 240 patients met the inclu-
sion criteria and were enrolled. These inpatients
were divided into group A (treatment group) and B
(control group) in order of admission according to
the principles of randomization and control. The re-
search was performed simultaneously in three hos-
pitals. Two groups were given basic treatment that
included: controlled oxygen therapy, active and ef-
fective anti-infection, maintaining airway patency,
correcting O2 deficiency and CO2 retention, correct-
ing acid-base imbalance and electrolyte distur-
bance, reducing pulmonary hypertension and treat-
ing right heart failure, nutritional support and treat-
ment of complications. Group A was given basic
treatment and integrated Traditional Chinese Medi-
cine (TCM) differentiating therapy; group B was giv-
en basic therapy and a placebo that was similar in
appearance and taste to TCM medicinal broth of
pharmaceutical preparations, provided by Yibin
Pharmaceutical Company (Yibin, China, Wuliangye
Group).
RESULTS: The mortality in the treatment group de-
creased by 4.98% compared with the control
group. The treatment group reported improved
ventilation, corrected hypoxemia, improved nutri-
tional status and promoted digestive functions. It
also significantly improved the patient's self-life
skills, improved the patient's quality of life and
could shorten the length of hospital stay.
CONCLUSION: Comprehensive integrated TCM-
WM treatment showed good clinical efficacy to-
ward the acute onset period of PHD patients.
© 2016 JTCM. All rights reserved.
Key words: integrated Traditional Chinese Medi-
cine and Western Medicine; Pulmonary heart dis-
ease; Treatment outcome; Multicenter study
INTRODUCTION
Chronic pulmonary heart disease (CPHD) is caused by
the persistent presence of pulmonary hypertension,
which can result in damage to cardiac function. When
the disease progresses to a decompensated state, the sit-
uation is normally dangerous, and without timely inter-
vention, death may result.1,2 The average prevalence rate
is 0.46% ,3 and the hospital mortality rate is 12.5%-
14.5% .4 Chronic obstructive pulmonary disease is
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closely related to PHD. The incidence of PHD is in-
creasing, thereby seriously affecting the quality of life
for patients.5-9 In recent years, researchers have carried
out studies on the complications of PHD from a patho-
physiological aspect.10-17 Extensive studies have been
performed to reduce pulmonary artery pressure and im-
prove respiratory failure and cardiopulmonary func-
tions. However, an effective approach to prevent heart
and lung function failure is still not available, and the
rates of mortality and mutilation remain high, placing
a heavy burden not only on patients and their families
but also on society.18-23 An acute exacerbation of PHD
is mostly induced by acute pulmonary infection, which
is normally accompanied by respiratory failure and car-
diac dysfunction. Complications such as acid-base im-
balance and electrolyte disturbance, pulmonary enceph-
alopathy, gastrointestinal bleeding, disseminated or dif-
fuse intravascular coagulation (DIC) and malnutrition
are life-threatening.12,14,15 Several studies investigated in-
tegrated Traditional Chinese Medicine-Western Medi-
cine (TCM-WM) for the treatment of acute onset peri-
od of PHD; however, the correct scientific methodolo-
gy was not used and the quality of clinical trials were
poor, which consequently affected the authenticity and
reproducibility of the conclusions. It is therefore diffi-
cult for worldwide medical circles to recognize the re-
sults, and thus the promotion and application of this
type of treatment is problematic. China is a low-in-
come country, and 70%-80% of patients live in rural
areas where PHD accounts for the highest mortality
rate. Therefore, it is necessary to develop a reasonable,
effective, safe and suitable integrated TCM-WM pro-
gram. Since 1994, clinical studies have been conducted
on integrated TCM-WM in the treatment of acute on-
set period of CPHD. The results showed that the appli-
cation of integrated TCM-WM could contribute to pa-
tients' recovery from infection, and reduce the period
of antibiotic use and hospitalization time. Clinical stud-
ies with large samples were carried out to prove the effi-
cacy and explore the value of the program.
MATERIALS ANDMETHODS
Study subjects
This study included 240 PHD patients who were in
the acute onset period. All subjects were inpatients of
the Department of Emergency (the Affiliated Hospital
of Chengdu University of Traditional Chinese Medi-
cine), Department of Emergency and Internal Medi-
cine (Neijiang Municipal Traditional Chinese Medici-
nal Hospital) and Department of Internal Medicine
(Anyue County Traditional Chinese Medicinal Hospi-
tal) from March 2004 to December 2006. These pa-
tients were divided randomly into an integrated
TCM-WM comprehensive treatment group (treatment
group) and Western Medicine (WM) comprehensive
treatment group (control group) according to the ad-
mission time. Seven cases were excluded from the
study because they did not follow their medication,
and three cases died within 24 h. A total of 230 cases
were included in which 114 cases were in the treat-
ment group and 116 cases were in the control group.
Five cases from the treatment group and 10 from the
control group did not continue the study. The statistic
of comprehensive efficacy was based on the last record-
ed data and the final data. The baselines of gender, age,
disease severity, symptoms and signs integral at the en-
rolment were homogeneous and comparable. This
study was conducted in accordance with the Declara-
tion of Helsinki24 and with approval from the Ethics
Committee of Chengdu University of Traditional Chi-
nese Medicine. Written informed consent was obtained
from all participants.
Inclusion criteria
The inclusion criteria were as follows: (a) chronic bron-
chitis, emphysema and heart disease or other chest dis-
eases caused by cardiovascular disease, pulmonary hy-
pertension, right ventricular enlargement and right ven-
tricular dysfunction, and acute exacerbation; (b) histo-
ry of chronic bronchitis; (c) aged 40-85 years old; (d)
within 72 h of onset; and (e) complied with the TCM
differentiating diagnosis of phlegmatic hygrosis reten-
tion in lung and closed and depressed lung Qi.
Exclusion criteria
Exclusion criteria were as follows: (a) non-chronic
bronchitis-caused PHD; (b) < 40 years old or > 85 years
old; (c) allergy to test drug; (d) severe liver and kidney
dysfunction (alanine aminotransferase, blood urea ni-
trogen and creatinine were more than twice normal lev-
els); (e) accompanied by severe diseases in the blood
system, endocrine and metabolic system, central ner-
vous system and other systems; mental illness; preg-
nant or lactating women; (f ) had serious complications
such as coma, shock, gastrointestinal bleeding, DIC,
pulmonary encephalopathy, pulmonary embolism, car-
diac arrhythmia and coronary heart disease when ad-
mitted; (g) died within 24 h of admission; (h) Hb <
6 g/dL; (i) was in the remission period of PHD, and (j)
did not comply with inclusion criterion 5. Patients
were excluded if any of the 10 criteria were not met.
Grouping
Patient grouping followed the principles of randomiza-
tion and control. The patients were divided into
groups A (integrated TCM-WM comprehensive treat-
ment group, the treatment group) and B (Western
Medicine comprehensive treatment group, the control
group). Based on the "Chronic Obstructive Pulmonary
Disease Treatment Guidelines" published by the
Chronic Obstructive Pulmonary Disease Group, Respi-
ratory Diseases Branch of Chinese Society in 2002,25
patients were divided into light, middle and severe.
The inpatients who met the inclusion criteria were dis-
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tributed into groups A and B according to the admis-
sion sequence. The program was simultaneously per-
formed at the three hospitals.
Randomization method
The research centers were sequenced in the following
order: Anyue County Traditional Chinese Medicinal
Hospital, Affiliated Hospital of Chengdu University of
Traditional Chinese Medicine, and Neijiang Municipal
Traditional Chinese Medicinal Hospital. The SAS soft-
ware PROC PLAN (version 8.0, SAS Institute, Chica-
go, IL, USA) was used to randomly generate the 'Test
Center Random Number Table' of the 240 cases, with
the center number as 3 and block as 6 (including the
20% cases lost and excluded).
Treatment methods
Basic treatment was carried out according to the
'Chronic Obstructive Pulmonary Disease Treatment
Guidelines' published by the Chronic Obstructive Pul-
monary Disease Group, Respiratory Diseases Branch of
Chinese Society in 2002.25 Basic treatments included
controlled oxygen therapy, active and effective anti-in-
fection, maintaining airway patency, correcting O2 defi-
ciency and CO2 retention, correcting acid-base imbal-
ance and electrolyte disturbance, reducing pulmonary
hypertension and treating right heart failure, nutrition-
al support and treatment of complications. Group A: ba-
sic treatment + integratedTCMdifferentiating therapy.
Basic syndromes
The basic syndromes for phlegmatic hygrosis retention
in lung and closed and depressed lung Qi were as fol-
lows: (a) coughing occasionally or frequently through-
out the day and night; excessive phlegm that was easy
to expectorate, or gummy and difficult to expectorate;
(b) white and thick, yellow white or purulent phlegm;
(c) chest tightness and asthma; (d) greasy mouth and
distended abdomen; and (e) pale and greasy tongue
proper and slippery pulse. Patients who possessed three
of the aforementioned five items combined with the
tongue symptoms could be diagnosed.
Treatment methods: facilitating the flow of gastric Qi
to relieve asthma, dissipate phlegm and relieve cough.
Drugs (pre-compounded prescription 1): ephedra, al-
mond, whole snake gourd fruit, bulbus allii, prepared
pinellia tuber, balloonflower root and licorice root.
Complex syndromes
Lung-spleen concurrent insufficiency: the complex syn-
dromes for lung-spleen concurrent insufficiency were
shortness of breath and difficulty breathing, fatigue,
low or hoarse voice, pale complexion, loss of appetite
or feeling full with little intake, loose or less stool, pale
tongue and weak pulse.
Treatment methods: facilitating the flow of gastric Qi
to relieve asthma, dissipate phlegm and relieve cough
and strengthen the spleen and lungs.
Drugs (pre-compounded prescription 2): pre-com-
pounded prescription 1, plus saussureae, villous amon-
mum fruit, tangerine peel, pilose asiabell root, Yun
Ling and fried atractylodes.
Hydroretention with asthenic Yang: the complex syn-
dromes included panicky and palpitating patients and
cough and upbored Qi. Minor patient movement in-
duced asthma and patients could tolerate a supine posi-
tion. Other symptoms were a swollen body, especially
the lower limbs; dark, low urine output; feeling cold in
the body and extremities; pale or dark purple tongue,
with white slippery tongue coating; and minor or oc-
clusive pulse.
Treatment methods: facilitating the flow of gastric Qi
to relieve asthma, dissipate phlegm and relieve cough
and warm Yang and alleviate water.
Drugs (pre-compounded prescription 3): pre-com-
pounded prescription 1, plus yun ling, cassia barktree
twig, fried atractylodes and oriental waterplantain tuber.
TCM decoction method: Every two prescriptions were
initially soaked for 30 min with 1600 mL of water.
The Donghua extracting machine (South Korea) was
used to boil the prescriptions for 40 min with a con-
stant pressure of 1.5 ATM and a temperature of
120 ℃ . The extract was then concentrated, divided
and packaged into six vacuum plastic bags, with
100 mL in each bag. This was administered to the pa-
tient orally thrice a day, one bag each time. All TCM
decoction pieces were purchased from Sichuan Herbal
Medicine Decoction Co., Ltd. (No 1618 Xiqu Ave
Hongguang Town, Pi County, Chengdu, China).
Group B: basic therapy + placebo
A total of 100 mL of placebo was administered with
the same approach as group A. The placebo was given
thrice a day within 30 min after a meal with warm wa-
ter. The placebo was provided by Yibin Pharmaceutical
Company (Yibin, China), Wuliangye Group, in the
same package as the therapeutic drug (the placebo was
of similar appearance and taste to TCM medicinal
broth of pharmaceutical preparations). The treatment
course was 14 days.
Observations
Mortality, comprehensive efficacy assessment and self-life
skill assessment were recorded.
Efficacy evaluation
Mortality rate was calculated as follows: 14-day mortal-
ity = death cases/total cases × 100% . Efficacy evalua-
tion after a 14-day comprehensive treatment was per-
formed according to the nimodipine score method (to-
tal score of the main symptoms and signs before treat-
ment-total score of the main symptoms and signs after
treatment)/total score of the main symptoms and signs
before treatment × 100%; clinical control > 85%; excel-
lent: 85%-61%; effective: 60%-30%; invalid: < 30%.
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Statistical analysis
The measurement data were expressed as the mean ±
standard deviation ( xˉ ± s), and the data were pro-
cessed using the SPSS statistical software (version 13.0,
SPSS Institute, Chicago, IL, USA). After the normal
distribution test and homogeneity test of variance, the
intergroup data were tested with the independent sam-
ple t-test, and the intragroup data were tested with
one-way analysis of variance. Data with homogeneity
of variance used the Least Significant Difference meth-
od, otherwise Tamhane's T2 method was used. The
counting data used the χ2 test and ranked data used
rank correlation. The comparison of clinical efficacy
and disease efficacy took the impact of center into ac-
count and used the Cochran-Mantel-Haenszel χ2 test.
RESULTS
Overall efficacy and turnover (Figure 1)
Table 1 shows that in group A, 11 cases were clinically
controlled, 61 were excellent, 19 were effective, eight
were invalid and 10 died. In group B, nine cases were
clinically controlled, 44 were excellent, 31 were effec-
tive, seven were invalid and 15 died. After the nonpara-
metric rank sum test for independent samples in the
two groups, the results exhibited a statistically signifi-
cant difference (P = 0.045 < 0.05). The overall efficacy
of group A was better than group B.
Overall clinical evaluation
Table 2 shows that after considering the central effects,
the intergroup was χ2CMH = 4.095 (P = 0.043). The in-
tergroup comparison showed P = 0.043 (< 0.05), sug-
gesting that the effects in different centers were better
than group B.
Table 3 shows that after considering the central effects,
the intergroup was χ2CMH = 5.227 (P = 0.022). Consid-
ering the different severities, the comparison between
groups A and B showed a significant difference (P =
0.022 < 0.05). This result indicates the different dis-
ease severities, and the efficacy of group A was better
than group B.
Mortality
The mortality comparison between the two groups
showed no significant difference (Table 4, P = 0.260, >
0.05), indicating that the treatment could not reduce
mortality.
Self-viability scores and acute onset comparison
In groups A and B, nine and 10 patients were lost to
follow-up, respectively, at 1 month. At 6 months, 22
patients in group A and 21 in group B were lost to fol-
Figure 1 Flowchart of the study
Included patients (n = 240)
Group A
(n = 120)
Group B
(n = 120)
Basic treatment and inte-
grated TCM differentiating
therapy (n = 120)
Uncomplex syndromes
(n = 35) Complex syndromes(n = 85)
Basic treatment and
Placebo (n = 120)
Precompounded
prescription 1 (n = 35)
Lung-spleen
concurrent
insufficiency
(n = 62)
Lung-spleen
concurrent
insufficiency
(n = 23)
Precompounded
prescription 2
(n = 62)
Precompounded
prescription 3
(n = 23)
Analyzed (n = 240)
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Statistical analysis
The measurement data were expressed as the mean ±
standard deviation ( xˉ ± s), and the data were pro-
cessed using the SPSS statistical software (version 13.0,
SPSS Institute, Chicago, IL, USA). After the normal
distribution test and homogeneity test of variance, the
intergroup data were tested with the independent sam-
ple t-test, and the intragroup data were tested with
one-way analysis of variance. Data with homogeneity
of variance used the Least Significant Difference meth-
od, otherwise Tamhane's T2 method was used. The
counting data used the χ2 test and ranked data used
rank correlation. The comparison of clinical efficacy
and disease efficacy took the impact of center into ac-
count and used the Cochran-Mantel-Haenszel χ2 test.
RESULTS
Overall efficacy and turnover (Figure 1)
Table 1 shows that in group A, 11 cases were clinically
controlled, 61 were excellent, 19 were effective, eight
were invalid and 10 died. In group B, nine cases were
clinically controlled, 44 were excellent, 31 were effec-
tive, seven were invalid and 15 died. After the nonpara-
metric rank sum test for independent samples in the
two groups, the results exhibited a statistically signifi-
cant difference (P = 0.045 < 0.05). The overall efficacy
of group A was better than group B.
Overall clinical evaluation
Table 2 shows that after considering the central effects,
the intergroup was χ2CMH = 4.095 (P = 0.043). The in-
tergroup comparison showed P = 0.043 (< 0.05), sug-
gesting that the effects in different centers were better
than group B.
Table 3 shows that after considering the central effects,
the intergroup was χ2CMH = 5.227 (P = 0.022). Consid-
ering the different severities, the comparison between
groups A and B showed a significant difference (P =
0.022 < 0.05). This result indicates the different dis-
ease severities, and the efficacy of group A was better
than group B.
Mortality
The mortality comparison between the two groups
showed no significant difference (Table 4, P = 0.260, >
0.05), indicating that the treatment could not reduce
mortality.
Self-viability scores and acute onset comparison
In groups A and B, nine and 10 patients were lost to
follow-up, respectively, at 1 month. At 6 months, 22
patients in group A and 21 in group B were lost to fol-
low-up. Table 5 shows that a statistical significance in
the self-life viability scores was not observed between
the two groups before treatment (P > 0.05). After a
14-day treatment, the self-life viability scores of the
two groups at the 1-month and 6-month follow-up
were lower than before the treatment, with statistical
significance (P < 0.05). The self-life viability scores in
group A were significantly lower than those of group B
(P < 0.05) after a 14-day treatment.
No significant difference was observed in the acute on-
set between the two groups at 6 months after treat-
ment (Table 6, P > 0.05).
Blood gas changes
Table 7 shows that no significant difference was ob-
served in PaCO2 and PaO2 of the two groups before
treatment (P > 0.05). Three days after treatment the
PaCO2 of both groups decreased, whereas the PaO2 in-
creased and exhibited statistical significance compared
with the results before treatment (P < 0.05). The inter-
group comparison showed that the PaO2 in group A
was significantly higher, and PaCO2 exhibited statisti-
cal significance and decreased in both groups (P <
0.05). Seven days after treatment, PaCO2 decreased in
both groups, whereas PaO2 increased and exhibited sta-
tistical significance compared with the results before
treatment (P < 0.05). The intergroup comparison
showed that the PaO2 in group A was significantly
higher, and PaCO2 exhibited statistical significance and
decreased in both groups (P < 0.05). PaCO2 decreased
inbothgroups,whereasPaO2 increased (P<0.05)14 days
after treatment. The intergroup comparison showed
Group
A
B
n
109
106
Clinical control (%)
11 (10.1)a
9 (8.5)
Excellent (%)
61 (56.0)a
44 (41.5)
Effective (%)
19 (17.4)a
31 (29.3)
Invalid (%)
8 (7.3)a
7 (6.6)
Death (%)
10 (9.2)a
15 (14.1)
Z value
－2.0
-
P value
0.05
-
Notes: group A was given basic treatment and integrated Traditional Chinese Medicine differentiating therapy; group B was given basic
therapy and placebo. Compared with group B, aP < 0.05.
Table 1 Comparison of clinical overall efficacy in the two groups
Center
1
2
3
Group
A
B
A
B
A
B
n
36
35
36
36
37
35
n (%)
1 (2.8)
4 (11.4)
4 (11.1)
4 (11.1)
6 (16.2)
1 (2.9)
Clinical control (%)
21 (58.3)
16 (45.7)
20 (55.6)
12 (33.3)
20 (54.1)
16 (45.7)
Excellent (%)
6 (16.7)
7 (20.0)
7 (19.4)
13 (36.1)
6 (16.2)
11 (31.4)
Effective (%)
5 (13.9)
3 (8.6)
2 (5.6)
3 (8.3)
1 (2.7)
1 (2.9)
Invalid (%)
3 (8.3)
5 (14.3)
3 (8.3)
4 (11.2)
4 (10.8)
6 (17.1)
Notes: group A was given basic treatment and integrated Traditional Chinese Medicine differentiating therapy; group B was given basic
therapy and placebo.
Table 2 Comparison of efficacy between the center and considering the efficacy of central effects
Different severity
Light
Middle
Severity
Group
A
B
A
B
A
B
n
4
5
48
45
57
56
n (%)
2 (50.0)
3 (60.0)
9 (18.8)
6 (13.3)
0 (0.0)
0 (0.0)
Clinical control (%)
0 (0.0)
1 (20.0)
28 (58.3)
19 (42.2)
33 (57.9)
24 (42.9)
Excellent (%)
1 (25.0)
0 (0.0)
6 (12.5)
15 (33.3)
12 (21.1)
16 (28.6)
Effective (%)
1 (25.0)
1 (20.0)
4 (8.3)
3 (6.7)
3 (5.3)
3 (5.4)
Invalid (%)
0 (0.0)
0 (0.0)
1 (2.1)
2 (4.5)
9 (15.7)
13 (23.1)
Notes: group A was given basic treatment and integrated Traditional Chinese Medicine differentiating therapy; group B was given basic
therapy and placebo.
Table 3 Comparison of efficacy between the severity of the disease and considering the efficacy of effects
Group
A
B
n
109
106
Death cases
10a
15
Mortality rate (%)
9.17
14.15
χ2 value
1.30
-
P value
0.26
-
Notes: group A was given basic treatment and integrated Traditional Chinese Medicine differentiating therapy; group B was given basic
therapy and placebo. Compared with group B, aP < 0.05.
Table 4 Comparison mortality in the two groups
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that the PaO2 in group A was significantly higher, and
PaCO2 exhibited statistical significance and decreased
in both groups (P < 0.05).
Hospitalization days
The hospitalization days of group A were shorter than
group B, with statistical significance (Table 8, P <
0.05). This result indicates that the integrated
TCM-WM therapy could shorten hospital stay.
Total hospitalization cost
The integrated TCM-WM therapy could shorten hos-
pital stay and lower the hospitalization cost (Table 9).
DISCUSSION
The results showed that the comparison among the dif-
ferent centers or the disease severity comparison sug-
gested that the efficacy of an integrated TCM-WM pro-
gram was better than the conventional Western Medi-
cine program. Although the effects of the two groups
in reducing mortality were considerably equal (P >
0.05), the mortality of group A decreased by 4.98%
compared with group B, indicating that the treatment
reduced mortality. The main reasons for the efficacy of
this program were three-fold. First, the program used
the method of releasing lung phlegm and dissipating it,
which promoted phlegm drainage and helped patients
recover from infection. Second, the program combined
the method of strengthening spleen and lung and pro-
moting food intake, thus improving nutritional status
and immunity. Third, the program combined the
method of warming Yang and alleviating water, improv-
Group
A
B
Before
n
109
106
Score
6.9±1.0
7.0±1.0
14 days after
n
109
106
Score
4.2±1.1ab
4.8±1.0a
1 Month after
n
109
106
Score
3.4±0.8ab
3.9±1.00a
6 Months after
n
109
106
Score
2.6±0.7ab
3.1±0.8a
Notes: group A was given basic treatment and integrated Traditional Chinese Medicine differentiating therapy; group B was given basic
therapy and placebo. Compared with the results before treatment, aP < 0.05, compared with group B, bP < 0.05.
Table 5 Self-viability scores of the two groups before and after treatment ( xˉ ± s)
Group
A
B
1-month after cases
109
106
Acute onset
0.3±0.5a
0.6±0.7
6-Month after cases
109
106
Acute onset
0.9±0.7
1.0±0.8
Notes: group A was given basic treatment and integrated Traditional Chinese Medicine differentiating therapy; group B was given basic
therapy and placebo. Compared with group B, aP < 0.05.
Table 6 Comparison of acute onset of the two groups ( xˉ ± s)
Group
A
B
Time
Before
3 days after
7 days after
14 days after
Before
3 days after
7 days after
14 days after
n
109
109
109
109
106
106
106
106
PaCO2 (Kpa)
8.7±1.3
7.8±1.3ab
7.2±1.2ab
6.7±1.2ab
8.9±1.1
8.2±1.1a
7.6±1.3a
7.0±1.4a
PaO2 (Kpa)
7.6±1.3
8.3±0.9ab
9.4±0.9ab
10.7±1.5ab
7.4±0.8
7.9±0.9a
8.8±1.3a
9.8±1.5a
Table 7 Changes of the blood and gas analysis between the two groups before and after treatment ( xˉ ± s)
Notes: group A was given basic treatment and integrated Traditional Chinese Medicine differentiating therapy; group B was given basic
therapy and placebo. Compared with the results before treatment, aP < 0.05; compared with group B, bP < 0.05.
Group
A
B
n
114
116
Time (days)
17±3a
19±4
Z value
3.5
-
P value
0.00
-
Notes: group A was given basic treatment and integrated Tradi-
tional Chinese Medicine differentiating therapy; group B was
given basic therapy and placebo. Compared with group B, aP <
0.05.
Table 8 Comparison of hospitalization days of the two
groups ( xˉ ± s)
Group
A
B
n
114
116
Total hospitalization
cost (RMB)
5258±144a
7051±148
Z
value
92.95
-
P
value
0.00
-
Notes: group A was given basic treatment and integrated Tradi-
tional Chinese Medicine differentiating therapy; group B was
given basic therapy and placebo. Compared with group B, aP <
0.05.
Table 9 Comparison of total hospitalization cost of the two
groups ( xˉ ± s)
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ing the heart and lung function and avoiding the use
of diuretic-induced electrolyte imbalance. Meanwhile,
TCM was rich in K+, which could be compensated by
oral administration of TCM, and prevented hypokale-
mia alkalosis.
The efficacy of the program could be analyzed as fol-
lows. The two treatment programs could alleviate pri-
mary and secondary symptoms. The efficacy of group
A was much more noticeable, especially prominent in
relieving cough, expectoration and asthma symptoms,
increasing appetite, and reducing bloating. This find-
ing suggests that the comprehensive program could in-
crease appetite and improve digestion. The effect-ob-
taining time of group A was shorter and helped short-
en the course of treatment. The effect-obtaining time
of group A might be associated with the better effects
of TCM in facilitating expectoration of phlegm in
lungs and cough relief, strengthening of spleen, benefit-
ting Qi, warming Yang and alleviating water. When the
lung circulation was normal, the cough would be
self-balanced. When the spleen was healthy, the stom-
ach could digest food, the phlegm would be dissolved,
the Qi function and body fluid circulation would be
smooth and the clinical symptoms would be cured.
The test results showed that the two treatment pro-
grams could improve the signs, but the integrated
TCM-WM comprehensive treatment exhibited more
noticeable advantages in improving wheezing, respirato-
ry rate, consciousness, cyanosis and edema. The ef-
fect-starting time was significantly shortened compared
with conventional Western Medicine treatment. This
result indicates that the integrated TCM-WM had ob-
vious synergies in relieving dyspnea, improving ventila-
tion, correcting hypoxia, promoting infection control
and inflammation absorption.
The daily activities of CPHD patients are restricted be-
cause of cardiopulmonary dysfunction. The quality of
life of these patients can decline in all aspects, especial-
ly in the acute onset period, which mainly appears as
viability that significantly reduces or is even lost. There-
fore, self-life viability is also an important sign of dis-
ease severity. This study showed that no statistical sig-
nificance was observed between the two groups in
self-life viability scores before treatment (P > 0.05). At
14 days after treatment and at the 1-month and
6-month follow-up, the self-life viability scores of the
two groups were lower than those before the treatment,
with statistical significance (P < 0.05). The scores in
group A were significantly lower than those in group
B, with statistical significance (P < 0.05). The number
of acute onset cases reduced 1 month after the treat-
ment (P < 0.05), suggesting that integrated TCM-WM
treatment had noticeable advantages in improving the
viability of CPHD patients.
The research results suggested that integrated TCM-
WM treatment could shorten the hospitalization stay.
The comparison of the total hospitalization cost be-
tween the two groups indicated that the cost of group
B was significantly higher than that of group A (P <
0.05), indicating that integrated TCM-WM treatment
could reduce the medical cost. Integrated TCM-WM
could also shorten the treatment time, dilute phlegm,
promote the drainage of phlegm, increase the effect of
anti-infection treatment and reduce the grade of antibi-
otics. These effects not only have the advantages of eas-
ing the patient's condition and improving quality of
life, but also reduce and save hospitalization and medi-
cal costs and are more suitable for the condition of Chi-
nese populations.
In summary, an integrated TCM-WM comprehensive
treatment program showed comprehensive clinical effi-
cacy toward the acute onset period of CPHD patients.
These findings were mainly observed in resolving
phlegm drainage problems, improving gastrointestinal
functions, promoting nutritional recovery in patients
and maintaining the avoidance of water and electrolyte
balance because of the correction of heart and lung
functions. The program exhibited a reducing trend in
mortality. It could improve patients' symptoms, pro-
mote patients' recovery from infection, shorten the pe-
riod of antibiotic use and time of hospitalization, and
reduce hospitalization cost.
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